Skip to main content

ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.

Publication ,  Journal Article
Zhu, L; Li, Q; Wong, SHK; Huang, M; Klein, BJ; Shen, J; Ikenouye, L; Onishi, M; Schneidawind, D; Buechele, C; Hansen, L; Duque-Afonso, J ...
Published in: Cancer discovery
July 2016

Numerous studies in multiple systems support that histone H3 lysine 36 dimethylation (H3K36me2) is associated with transcriptional activation; however, the underlying mechanisms are not well defined. Here, we show that the H3K36me2 chromatin mark written by the ASH1L histone methyltransferase is preferentially bound in vivo by LEDGF, a mixed-lineage leukemia (MLL)-associated protein that colocalizes with MLL, ASH1L, and H3K36me2 on chromatin genome wide. Furthermore, ASH1L facilitates recruitment of LEDGF and wild-type MLL proteins to chromatin at key leukemia target genes and is a crucial regulator of MLL-dependent transcription and leukemic transformation. Conversely, KDM2A, an H3K36me2 demethylase and Polycomb group silencing protein, antagonizes MLL-associated leukemogenesis. Our studies are the first to provide a basic mechanistic insight into epigenetic interactions wherein placement, interpretation, and removal of H3K36me2 contribute to the regulation of gene expression and MLL leukemia, and suggest ASH1L as a novel target for therapeutic intervention.Epigenetic regulators play vital roles in cancer pathogenesis and represent a new frontier in therapeutic targeting. Our studies provide basic mechanistic insight into the role of H3K36me2 in transcription activation and MLL leukemia pathogenesis and implicate ASH1L histone methyltransferase as a promising target for novel molecular therapy. Cancer Discov; 6(7); 770-83. ©2016 AACR.See related commentary by Balbach and Orkin, p. 700This article is highlighted in the In This Issue feature, p. 681.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer discovery

DOI

EISSN

2159-8290

ISSN

2159-8274

Publication Date

July 2016

Volume

6

Issue

7

Start / End Page

770 / 783

Related Subject Headings

  • Transcription Factors
  • Protein Binding
  • Promoter Regions, Genetic
  • Nucleosomes
  • Myeloid-Lymphoid Leukemia Protein
  • Mice
  • Methylation
  • Lysine
  • Leukemia
  • Jumonji Domain-Containing Histone Demethylases
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zhu, L., Li, Q., Wong, S. H. K., Huang, M., Klein, B. J., Shen, J., … Cleary, M. L. (2016). ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia. Cancer Discovery, 6(7), 770–783. https://doi.org/10.1158/2159-8290.cd-16-0058
Zhu, Li, Qin Li, Stephen H. K. Wong, Min Huang, Brianna J. Klein, Jinfeng Shen, Larissa Ikenouye, et al. “ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.Cancer Discovery 6, no. 7 (July 2016): 770–83. https://doi.org/10.1158/2159-8290.cd-16-0058.
Zhu L, Li Q, Wong SHK, Huang M, Klein BJ, Shen J, et al. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia. Cancer discovery. 2016 Jul;6(7):770–83.
Zhu, Li, et al. “ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia.Cancer Discovery, vol. 6, no. 7, July 2016, pp. 770–83. Epmc, doi:10.1158/2159-8290.cd-16-0058.
Zhu L, Li Q, Wong SHK, Huang M, Klein BJ, Shen J, Ikenouye L, Onishi M, Schneidawind D, Buechele C, Hansen L, Duque-Afonso J, Zhu F, Martin GM, Gozani O, Majeti R, Kutateladze TG, Cleary ML. ASH1L Links Histone H3 Lysine 36 Dimethylation to MLL Leukemia. Cancer discovery. 2016 Jul;6(7):770–783.

Published In

Cancer discovery

DOI

EISSN

2159-8290

ISSN

2159-8274

Publication Date

July 2016

Volume

6

Issue

7

Start / End Page

770 / 783

Related Subject Headings

  • Transcription Factors
  • Protein Binding
  • Promoter Regions, Genetic
  • Nucleosomes
  • Myeloid-Lymphoid Leukemia Protein
  • Mice
  • Methylation
  • Lysine
  • Leukemia
  • Jumonji Domain-Containing Histone Demethylases